RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

DSpace/Manakin Repository

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

Citable link to this page

 

 
Title: RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Author: Xiao, Yanping; Yu, Sanhong; Zhu, Baogong; Bedoret, Denis; Bu, Xia; Francisco, Loise M.; Hua, Ping; Duke-Cohan, Jonathan S.; Umetsu, Dale T.; Sharpe, Arlene H.; DeKruyff, Rosemarie H.; Freeman, Gordon J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Xiao, Y., S. Yu, B. Zhu, D. Bedoret, X. Bu, L. M. Francisco, P. Hua, et al. 2014. “RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance.” The Journal of Experimental Medicine 211 (5): 943-959. doi:10.1084/jem.20130790. http://dx.doi.org/10.1084/jem.20130790.
Full Text & Related Files:
Abstract: We report that programmed death ligand 2 (PD-L2), a known ligand of PD-1, also binds to repulsive guidance molecule b (RGMb), which was originally identified in the nervous system as a co-receptor for bone morphogenetic proteins (BMPs). PD-L2 and BMP-2/4 bind to distinct sites on RGMb. Normal resting lung interstitial macrophages and alveolar epithelial cells express high levels of RGMb mRNA, whereas lung dendritic cells express PD-L2. Blockade of the RGMb–PD-L2 interaction markedly impaired the development of respiratory tolerance by interfering with the initial T cell expansion required for respiratory tolerance. Experiments with PD-L2–deficient mice showed that PD-L2 expression on non–T cells was critical for respiratory tolerance, but expression on T cells was not required. Because PD-L2 binds to both PD-1, which inhibits antitumor immunity, and to RGMb, which regulates respiratory immunity, targeting the PD-L2 pathway has therapeutic potential for asthma, cancer, and other immune-mediated disorders. Understanding this pathway may provide insights into how to optimally modulate the PD-1 pathway in cancer immunotherapy while minimizing adverse events.
Published Version: doi:10.1084/jem.20130790
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010901/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454707
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters